Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)

PHASE3CompletedINTERVENTIONAL
Enrollment

423

Participants

Timeline

Start Date

October 30, 2019

Primary Completion Date

March 17, 2022

Study Completion Date

March 17, 2022

Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
DRUG

GV1001 placebo

0.9 % Normal Saline

DRUG

Proscar placebo

PO

Trial Locations (23)

Unknown

Hanyang University Guri Hospital, Guri-si

Seoul National University Bundang Hospital, Seongnam-si

Dongguk University Gyeongju Hospital, Gyeongju

Hallym University Medical Center, Anyang

Inje University Busan Paik Hospital, Busan

Samsung Changwon Medical Center, Changwon

Soonchunhyang University Hospital, Cheonan

Daegu Catholic University Medical Center, Daegu

Keimyung University Dongsan Medical Center, Daegu

Kyungpook National University Chilgok Hospital, Daegu

Yeungnam University Medical Center, Daegu

Dongguk University Ilsan Hospital, Ilsan

Jeonbuk National University Hospital, Jeonju

Chungbuk National University Hospital, Jungbuk

Chonnam National University Hospital, Jungnam

Asan Medical Center, Seoul

Chung-ang University Hospital, Seoul

Eulji General Hospital, Seoul

Korea University Guro Hospital, Seoul

Samsung Medical Center, Seoul

Severance Hospital, Seoul

The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul

Pusan National University Yangsan Hospital, Yangsan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GemVax & Kael

INDUSTRY